The company also inked a deal with an investment bank to publicly offer from time to time up to $4.2 million of its stock.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.
The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.
The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.
Patrick Muraca, the former CEO of Nuclea Biotechnologies and NanoMolecularDx, was already serving a prison term of more than two years.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D.
In May, the company received a delisting warning from Nasdaq after its stock closed between the minimum $1 per share requirement for 30 days.
Anpac currently offers a test in China for detecting the risk of 26 cancer types using the firm's so-called cancer differentiation analysis technology.
The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.